On July 16, CARsgen Therapeutics-B rose 5.51% in regular trading, trading at HK$16.89/share, with turnover of HK$29.95 million.

On the news front, the company announced on July 15 that preliminary positive results from an investigator-initiated clinical trial of Kelimei (Satricabtagene Autoleucel) for post-adjuvant consolidation therapy in gastric/gastroesophageal junction adenocarcinoma have been accepted for poster presentation at the European Society for Medical Oncology Annual Meeting. The abstract is scheduled for publication on October 19 on the ESMO website.

Since enrollment began in May of last year, all participants who received Kelimei treatment have shown no post-surgical recurrence or metastasis. Kelimei is the world's first approved CAR-T cell therapy product for solid tumors, having received NMPA approval in June for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. This exploration into post-surgical consolidation therapy further expands the product's indication potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)